

November 7, 2019



## Poxel to Present at Upcoming Investor Conferences

LYON, France--(BUSINESS WIRE)-- [POXEL S.A.](#) (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will present at two upcoming investor conferences in November:

### **William Blair Boston Innovation Day**

**Date:** November 12, 2019

**Time:** 9:00 am EST

**Location:** 200 Claredon Street, Boston, MA

### **Jefferies 2019 London Healthcare Conference**

**Date:** November 20, 2019

**Time:** 1:20 pm GMT

**Location:** Waldorf Hilton, London, UK

The Jefferies 2019 London Healthcare Conference presentation will be live streamed via webcast.

To access the webcast, please visit: <http://wsw.com/webcast/jeff123/poxel.pa/>. The webcast replay will remain available for 90 days following the live presentation.

### **About Poxel SA**

Poxel is a **dynamic biopharmaceutical company** that uses its extensive expertise in developing **innovative drugs for metabolic diseases**, with a focus on **type 2 diabetes** and **non-alcoholic steatohepatitis (NASH)**. In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. **Imeglimin**, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 **Trials of IMeglimin for Efficacy and Safety (TIMES)** program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. **PXL065** (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of

NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: [www.poxelpharma.com](http://www.poxelpharma.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20191107005717/en/>

**Poxel SA** □

Jonae R. Barnes

Senior Vice President, Investor Relations and Public Relations

[jonae.barnes@poxelpharma.com](mailto:jonae.barnes@poxelpharma.com)

+1 617 818 2985

Aurélie Bozza

Investor Relations & Communication Director

[aurelie.bozza@poxelpharma.com](mailto:aurelie.bozza@poxelpharma.com)

+33 6 99 81 08 36

**Investor relations / Media - EU/US**

Trophic Communications

Stephanie May or Joanne Tudorica

[may@trophic.eu](mailto:may@trophic.eu) or [tudorica@trophic.eu](mailto:tudorica@trophic.eu)

+49 89 238 877 34 or +49 171 185 56 82

**Investor relations / Media - France**

NewCap

Alexia Faure / Arthur Rouillé

[poxel@newcap.eu](mailto:poxel@newcap.eu)

+33 1 44 71 94 94

Source: Poxel SA